Table 4.
Risk factors for MAC-PD mortality.
| Censored (n = 247) | Death (n = 48) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| p-value | HR (95%CI) | p-value | Adjusted HR (95%CI) | |||
| Characteristic | ||||||
| Sex, male | 49 (11.7) | 21 (44.7) | 0.0002* | 3.19 (1.77–5.71) | < .0001* | 3.00 (1.50–5.92) |
| Age, years | 65.3 (± 10.6) | 69.1 (± 9.4) | 0.0008* | 1.06 (1.02–1.10) | 0.0315* | 1.04 (1.00–1.08) |
| BMI | 18.9 (± 2.6) | 17.4 (± 2.9) | < .0001* | 0.76 (0.66–0.87) | < .0001* | 0.80 (0.70–0.91) |
| Underlying disease | ||||||
| COPD | 7 (2.8) | 8 (17.0) | 0.0046* | 3.56 (1.54–7.23) | 0.2279 | 1.88 (0.66–4.97) |
| Old Tb | 7 (2.8) | 8 (17.0) | 0.003* | 3.83 (1.66–7.80) | 0.0247* | 3.10 (1.15–9.12) |
| DM | 16 (6.5) | 11 (23.4) | 0.0005* | 4.02 (1.94–7.70) | 0.0188* | 2.84 (1.20–6.40) |
| CPA | 1 (0.4) | 2 (4.3) | 0.0072* | 16.3 (2.60–56.1) | 0.0502 | 7.32 (0.998–35.55) |
| CRP | 1.1 (± 2.1) | 2.4 (± 2.5) | < .0001* | 1.23 (1.13–1.33) | < .0001* | 1.22 (1.06–1.41) |
| NB form | 212 (85.5) | 37 (78.7) | 0.1846 | 0.61 (0.31–1.29) | ||
| Cavity | 92 (37.2) | 35 (72.9) | < .0001* | 4.24 (2.27–8.45) | 0.0472* | 2.11 (1.01–4.56) |
| M. avium | 143 (57.7) | 17 (36.2) | 0.0028* | 0.41 (0.22–0.74) | 0.0106* | 0.44 (0.23–0.83) |
| AFB stain positive | 94 (37.9) | 29 (61.7) | 0.0123* | 2.09 (1.17–3.84) | ||
| Standard regimen | 201 (81.0) | 37 (78.7) | Ref | 1.00 | ||
| Alternative regimen | 47 (19.0) | 10 (21.3) | 0.7212 | 1.68 (0.88–3.46) | ||
| Aminoglycoside use | 74 (29.8) | 11 (23.4) | 0.1173 | 0.60 (0.29–1.13) | ||
| Adjuvant surgery | 10 (4.0) | 0 (0.0) | 0.0822 | 0.0793 | ||
Data represent n (%) or median (interquartile range).
MAC-PD Mycobacterium avium complex pulmonary disease; HR hazard ratio; CI confidence interval; BMI body mass index; COPD chronic obstructive pulmonary disease; Tb tuberculosis; DM, diabetes mellitus; CRP C-reactive protein; NB nodular bronchiectasis; CPA chronic pulmonary aspergillosis.